Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
InSilico Medicine Cayman TopCo ( (HK:3696) ) has issued an announcement.
InSilico Medicine has entered into a multi-year research and development collaboration with French pharmaceutical group Servier to discover and develop new oncology therapies, in a deal valued at up to US$888 million. Under the agreement, InSilico will lead AI-driven discovery using its Pharma.AI platform and is eligible for up to US$32 million in upfront and near-term R&D payments, while Servier will share development costs and take charge of clinical validation, regulatory work and global commercialization of successful drug candidates, a structure that underscores growing industry confidence in AI-enabled drug development and could accelerate the expansion and monetization of InSilico’s oncology pipeline.
More about InSilico Medicine Cayman TopCo
InSilico Medicine Cayman TopCo is an AI-driven drug discovery company that develops novel therapeutics by applying its proprietary Pharma.AI platform, with a strong focus on oncology. The company has built a robust cancer pipeline targeting multiple indications, including pan-TEAD inhibitor ISM6331 and MAT2A inhibitor ISM3412 now in global Phase I trials, and has out-licensed several additional oncology programs to partners.
Average Trading Volume: 17,290,761
Current Market Cap: HK$20.95B
For an in-depth examination of 3696 stock, go to TipRanks’ Overview page.